SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu
Negative Breast Cancer.
This is a clinical trial of everolimus that will be administered by mouth which is investigational and hormone treatment that will be administered by mouth and subcutaneous injection and is standard of care.
IRB Protocol #
CANDICE GILLMANN at (720)848-0663 or CANDICE.GILLMANN@UCDENVER.EDU
University of Colorado Hospital University of Colorado Hospital
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last up to 54 weeks. A follow up period will consist of clinic visits. // Eligibility criteria include but are not limited to 18 years or older with breast cancer.Eligibility criteria include but are not limited to 18 years or older with breast cancer.